Immunology/Inflammation

Immunology/Inflammation(免疫及炎症)

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

研究方向

Immunology/Inflammation 相关产品(4245)

  • GC69899 structure
    GC69899SIRT6 activator 12q
    CAS: 2601734-99-8
    纯度: >98.00%

    SIRT6 activator 12q是一种SIRT6选择性激活剂(IC 50 =0.58μM)。

  • GC69908 structure
    GC69908Skatole-d3
    CAS: 111399-60-1
    纯度: >98.00%

    Skatole-d3 是 Skatole 的氘代物。Skatole 是肠道菌群产生的物质,通过激活芳基烃受体 (aryl hydrocarbon receptors) 和 p38 调节肠上皮细胞功能。

  • GC69912 structure
    GC69912SLC7A11-IN-1
    纯度: >95.00%

    SLC7A11-IN-1 是一种有效的SLC7A11 抑制剂。SLC7A11-IN-1 显示出抗增殖活性。SLC7A11-IN-1 抑制细胞侵袭和转移。SLC7A11-IN-1 诱导细胞凋亡 (Apoptosis) 和细胞周期停滞在 S 期。SLC7A11-IN-1 具有抗肿瘤活性。

  • GC69937 structure
    GC69937Spesolimab
    CAS: 2097104-58-8
    纯度: >99.00%

    Spesolimab (BI 655130) 是一种抗 IL-36R 抗体。IL-36 在免疫系统中具有重要作用,Spesolimab 可用于掌跖脓疱病 (PPP) 的研究。Spesolimab 与先天性、Th1/Th17 和中性粒细胞途径相关的生物标志物的减少有关。

  • GC69943 structure
    GC69943SRI-42127
    CAS: 2727872-68-4
    纯度: >99.00%

    SRI-42127 是一种 HuR 易位抑制剂。HuR 是一种与 ARE 元件结合的 RNA 调节因子,HuR 易位可促进胶质细胞中炎性细胞因子的产生。而 SRI-42127 能够破坏 mRNA 稳定性并抑制基因启动子激活。SRI-42127 还抑制小胶质细胞活化,减弱中性粒细胞和单核细胞的募集/趋化作用。

  • GC69959 structure
    GC69959STING agonist-20
    CAS: 2591300-72-8
    纯度: >99.50%

    STING agonist-20 (compound 95) 是一种有效的 STING 激动剂,用于合成 XMT-2056。STING agonist-20 可作为疫苗佐剂,用于癌症以及其他炎症,免疫性疾病的研究。

  • GC69961 structure
    GC69961STING agonist-22
    CAS: 2408723-12-4

    STING agonist-22 (CF501) 是一种有效的非核苷酸 STING 激动剂。 STING agonist-22 是一种佐剂,通过激活 STING 来诱导 I 型干扰素 (IFN-I) 反应和促炎细胞因子的产生。 STING agonist-22 可用作增强原始蛋白疫苗的佐剂,产生有效、广泛和长期的免疫保护。 STING agonist-22 可用于 SARS-CoV-2 变异和 sarbecovirus 疾病研究。

  • GC69962 structure
    GC69962STING agonist-3 trihydrochloride

    STING agonist-3 trihydrochloride 源于专利 WO2017175147A1 (实施例10),是一种选择性和非核苷酸的小分子 STING 激动剂,pEC50 和 pIC50 分别为 7.5 和 9.5。STING agonist-3 trihydrochloride 具有持久的抗肿瘤作用,并且在改善癌症研究方面具有巨大潜力。

  • GC69963 structure
    GC69963STING agonist-8 dihydrochloride

    STING agonist-8 dihydrochloride (5-AB) 是一种有效 STING 激动剂,在 THP1-Dual KI-hSTING-R232 细胞中的 EC50 为 27 nM。

  • GC69998 structure
    GC69998TBK1-IN-1
    纯度: >98.00%

    TBK1-IN-1 是一种有效的选择性 TANK 结合激酶 1 (TBK1) 抑制剂,IC50 值为 22.4 nM。TBK1-IN-1 抑制 TBK1 下游靶基因 cxcl10 和 ifnβ 的表达。TBK1-IN-1 具有抗癌活性。

  • GC70004 structure
    GC70004Tebentafusp
    CAS: 1874157-95-5

    Tebentafusp (IMCgp100) 是一种双特异性融合蛋白,靶向 gp100 (一种黑色素瘤相关抗原)。Tebentafusp 通过高亲和力 T 细胞受体 (TCR) 结合域和抗 CD3 T 细胞接合域引导 T 细胞杀死表达 gp100 的肿瘤细胞。Tebentafusp 诱导炎性细胞因子和细胞溶解蛋白的产生,导致肿瘤细胞的直接裂解。

  • GC70017 structure
    GC70017Tesidolumab
    CAS: 1531594-08-7
    纯度: >95.00%

    Tesidolumab (LFG316) 是一种全人IgG1/Λ抗c5单克隆抗体,分子量为143 kDa(不含糖基化)。Tesidolumab (LFG316)阻断C5的切割,防止膜攻击复合体的后续形成。

  • GC70026 structure
    GC70026Thymidine 3',5'-diphosphate tetrasodium
    CAS: 118675-87-9
    纯度: >97.00%

    Thymidine 3',5'-diphosphate (Deoxythymidine 3′,5′-diphosphate) tetrasodium 是葡萄球菌核酸酶和含有 1 的都铎结构域 (SND1,MicroRNA 调控复合体 RISC 亚基) 与 [3,5-2H2] 酪氨酸核酸酶 ( [3,5-2H2] tyrosyl nuclease) 的选择性抑制剂。Thymidine 3',5'-diphosphate tetrasodium 具有抗肿瘤活性,在生化反应也可用作催化剂。

  • GC70034 structure
    GC70034TL8-506
    CAS: 1268163-15-0

    TL8-506 是一种特异性 TLR8 激动剂,EC50 为 30 nM。TL8-506 可用于结核病和自身免疫性疾病的研究。

  • GC70035 structure
    GC70035TLR7/8 agonist 1
    CAS: 1258457-59-8
    纯度: >96.00%

    TLR7/8 agonist 1是一种 toll 样受体 (TLR7)/TLR8 的双重激动剂。

  • GC70036 structure
    GC70036TLR9-IN-1
    CAS: 2226366-86-3
    纯度: >99.50%

    TLR9-IN-1 是一种有效且选择性的 TLR9 抑制剂,对人 TLR9 的 IC50 为 7 nM。TLR9-IN-1可用于研究不良免疫应答相关疾病。

  • GC70038 structure
    GC70038TMX-201
    CAS: 1149339-78-5
    纯度: >98.00%

    TMX-201 是一种 TLR7 配体-磷脂共轭物。TMX-201 显示出有效的的免疫刺激活性。TMX-201 可用于乳腺癌和黑色素瘤的研究。

  • GC70042 structure
    GC70042Tomaralimab
    CAS: 1449294-76-1
    纯度: >95.00%

    Tomaralimab (OPN-305) 是一种人源化的抗-TLR2 (anti-TLR2) IgG4 单克隆抗体。Tomaralimab 具有研究骨髓增生异常综合征 (MDS) 的潜力。

  • GC70045 structure
    GC70045Tozorakimab
    CAS: 2376858-66-9

    Tozorakimab (MEDI-3506) 是一种靶向白介素-33 (interleukin-33) 的人免疫球蛋白 G1 单克隆抗体。Tozorakimab 可用于研究慢性阻塞性肺疾病。

  • GC70116 structure
    GC70116Vesencumab
    CAS: 1205533-60-3
    纯度: >95.00%

    Vesencumab (MNRP-1685A) 是针对 neuropilin-1 (NRP-1) 的 IG1 抗体。Vesencumab 与 NRP-1 结合并阻止 NRP-1 与 VEGFR-2 偶联。Vesencumab 具有抗血管生成和抗肿瘤活性。Vesencumab可用于转移性实体瘤的研究,包括卵巢癌。

  • GC70119 structure
    GC70119Vipoglanstat
    CAS: 1360622-01-0
    纯度: >99.00%

    Vipoglanstat (BI 1029539),甲酰胺,是一种有效的,选择性的,非肽人前列腺素 E 合成酶 1 (mPGES-1) 小分子抑制剂,具有口服活性。Vipoglanstat 也具有抗炎活性。

  • GC70120 structure
    GC70120Vixarelimab
    CAS: 2243320-83-2
    纯度: >95.00%

    Vixarelimab (KPL-716) 是一种人源的抗 oncostatin M (OSM)单克隆抗体,可以与 OSM 受体的β链结合,抑制 IL-31 和 OSM 的信号传导。Vixarelimab 可用于特应性皮炎和结节性痒疹等皮肤炎症性疾病研究。

  • GC70154 structure
    GC70154Yakuchinone A
    CAS: 78954-23-1
    纯度: >97.00%

    Yakuchinone A 是一种可以从 Alpinia oxyphylla 果实分离得到的天然产物,可以诱导细胞凋亡 (apoptosis),具有抗癌、抗炎活性。

  • GC70170 structure
    GC70170Zilucoplan
    CAS: 1841136-73-9
    纯度: >97.00%

    Zilucoplan (RA101495) 是一种 15 个氨基酸的大环肽,是一种有效的补体成分 5 (C5) 抑制剂。Zilucoplan 可用于免疫介导的坏死性肌病 (IMNM) 研究。